Literature DB >> 26433551

The Globalization of Cooperative Groups.

Manuel Valdivieso1, Benjamin W Corn2, Janet E Dancey3, D Lawrence Wickerham4, L Elise Horvath5, Edith A Perez6, Alison Urton7, Walter M Cronin8, Erica Field9, Evonne Lackey10, Charles D Blanke11.   

Abstract

The National Cancer Institute (NCI)-supported adult cooperative oncology research groups (now officially Network groups) have a longstanding history of participating in international collaborations throughout the world. Most frequently, the US-based cooperative groups work reciprocally with the Canadian national adult cancer clinical trial group, NCIC CTG (previously the National Cancer Institute of Canada Clinical Trials Group). Thus, Canada is the largest contributor to cooperative groups based in the United States, and vice versa. Although international collaborations have many benefits, they are most frequently utilized to enhance patient accrual to large phase III trials originating in the United States or Canada. Within the cooperative group setting, adequate attention has not been given to the study of cancers that are unique to countries outside the United States and Canada, such as those frequently associated with infections in Latin America, Asia, and Africa. Global collaborations are limited by a number of barriers, some of which are unique to the countries involved, while others are related to financial support and to US policies that restrict drug distribution outside the United States. This article serves to detail the cooperative group experience in international research and describe how international collaboration in cancer clinical trials is a promising and important area that requires greater consideration in the future.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26433551      PMCID: PMC4592942          DOI: 10.1053/j.seminoncol.2015.07.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  202 in total

1.  Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Authors:  Monica M Bertagnolli; Mark Redston; Carolyn C Compton; Donna Niedzwiecki; Robert J Mayer; Richard M Goldberg; Thomas A Colacchio; Leonard B Saltz; Robert S Warren
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

2.  Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

Authors:  Nadine Norton; Rebecca M Olson; Mark Pegram; Kathleen Tenner; Karla V Ballman; Raphael Clynes; Keith L Knutson; Edith A Perez
Journal:  Cancer Immunol Res       Date:  2014-07-02       Impact factor: 11.151

3.  Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  E A Eisenhauer; W K Evans; D Raghavan; M J Desmeules; N R Murray; R Stuart-Harris; K S Wilson
Journal:  Cancer Treat Rep       Date:  1986-08

4.  RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Authors:  Tracey Schefter; Kathryn Winter; Janice S Kwon; Kelly Stuhr; Khalid Balaraj; Brian Patrick Yaremko; William Small; William Sause; David Gaffney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Authors:  Neal W Wilkinson; Greg Yothers; Samia Lopa; Joseph P Costantino; Nicholas J Petrelli; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2010-04       Impact factor: 5.344

7.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

Authors:  Irene L Wapnir; Stefan Aebi; Charles E Geyer; David Zahrieh; Richard D Gelber; Stewart J Anderson; André Robidoux; Jürg Bernhard; Rudolf Maibach; Monica Castiglione-Gertsch; Alan S Coates; Martine J Piccart; Mark J Clemons; Joseph P Costantino; Norman Wolmark
Journal:  Clin Breast Cancer       Date:  2008-06       Impact factor: 3.225

9.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Authors:  Sandra M Swain; Gong Tang; Charles E Geyer; Priya Rastogi; James N Atkins; Paul P Donnellan; Louis Fehrenbacher; Catherine A Azar; André Robidoux; Jonathan A Polikoff; Adam M Brufsky; David D Biggs; Edward A Levine; John L Zapas; Louise Provencher; Donald W Northfelt; Soonmyung Paik; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

Review 10.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

View more
  3 in total

1.  Conducting non-commercial international clinical trials: the ICR-CTSU experience.

Authors:  Lisa Fox; Christy Toms; Sarah Kernaghan; Claire Snowdon; Judith M Bliss
Journal:  Trials       Date:  2017-09-26       Impact factor: 2.279

2.  Landscape of Oncology Clinical Trials in Africa.

Authors:  Folakemi T Odedina; Delva Shamley; Ifeoma Okoye; Adaora Ezeani; Ntokozo Ndlovu; Yvonne Dei-Adomakoh; Kimberly Meza; Ruth Agaba; Parisa Fathi; Nissa Askins
Journal:  JCO Glob Oncol       Date:  2020-06

Review 3.  Challenges of international oncology trial collaboration-a call to action.

Authors:  Monica Tang; Heikki Joensuu; Robert J Simes; Timothy J Price; Sonia Yip; Wendy Hague; Katrin M Sjoquist; John Zalcberg
Journal:  Br J Cancer       Date:  2019-08-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.